An interview addressing the complex treatment pathway of RCC patients from therapies in the adjuvant through to third-line settings. Failed trials in the adjuvant setting and the low level of success in filling a large unmet need in this patient population are discussed, as well as hopes and predictions for key pipeline drugs. 

This interview was conducted on 4 April 2024. 

If you are a KOL Insight Subscriber, you may also access the interview from our KOL Insight portal. 

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.